Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Jul. 31, 2019 | Oct. 29, 2019 | Jan. 31, 2019 | |
Document And Entity Information | |||
Entity Registrant Name | PURE BIOSCIENCE, INC. | ||
Entity Central Index Key | 0001006028 | ||
Document Type | 10-K | ||
Document Period End Date | Jul. 31, 2019 | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --07-31 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business Flag | true | ||
Entity Emerging Growth Company | false | ||
Entity Ex Transition Period | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 39,000,000 | ||
Entity Common Stock, Shares Outstanding | 79,994,402 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2019 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Jul. 31, 2019 | Jul. 31, 2018 |
Current assets | ||
Cash and cash equivalents | $ 398,000 | $ 851,000 |
Accounts receivable | 373,000 | 275,000 |
Inventories, net | 177,000 | 197,000 |
Restricted cash | 75,000 | 75,000 |
Prepaid expenses | 18,000 | 58,000 |
Total current assets | 1,041,000 | 1,456,000 |
Property, plant and equipment, net | 362,000 | 461,000 |
Patents, net | 529,000 | 658,000 |
Total assets | 1,932,000 | 2,575,000 |
Current liabilities | ||
Accounts payable | 553,000 | 608,000 |
Promissory note payable | 503,000 | |
Accrued liabilities | 185,000 | 170,000 |
Total current liabilities | 738,000 | 1,281,000 |
Deferred rent | 4,000 | 13,000 |
Total liabilities | 742,000 | 1,294,000 |
Commitments and contingencies (See Note 4) | ||
Stockholders' equity | ||
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding | ||
Common stock, $0.01 par value: 100,000,000 shares authorized, 76,732,334 shares issued and outstanding at July 31, 2019, and 68,248,158 shares issued and outstanding at July 31, 2018 | 768,000 | 683,000 |
Additional paid-in capital | 123,900,000 | 117,522,000 |
Accumulated deficit | (123,478,000) | (116,924,000) |
Total stockholders' equity | 1,190,000 | 1,281,000 |
Total liabilities and stockholders' equity | $ 1,932,000 | $ 2,575,000 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Jul. 31, 2019 | Jul. 31, 2018 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | ||
Preferred stock, shares outstanding | ||
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 76,732,334 | 68,248,158 |
Common stock, shares outstanding | 76,732,334 | 68,248,158 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Income Statement [Abstract] | ||
Net product sales | $ 1,909,000 | $ 1,774,000 |
Operating costs and expenses | ||
Cost of goods sold | 728,000 | 763,000 |
Selling, general and administrative | 3,967,000 | 5,235,000 |
Research and development | 354,000 | 459,000 |
Share-based compensation | 2,449,000 | 2,359,000 |
Total operating costs and expenses | 7,498,000 | 8,816,000 |
Loss from operations | (5,589,000) | (7,042,000) |
Other income (expense) | ||
Change in derivative liability | 459,000 | |
Inducement to exercise warrants | (960,000) | (876,000) |
Interest expense, net | (6,000) | (8,000) |
Other income, net | 1,000 | 25,000 |
Total other expense | (965,000) | (400,000) |
Net loss | $ (6,554,000) | $ (7,442,000) |
Basic and diluted net loss per share | $ (0.09) | $ (0.11) |
Shares used in computing basic and diluted net loss per share | 72,880,484 | 67,279,124 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Deficit [Member] | Total |
Balance at Jul. 31, 2017 | $ 631,000 | $ 110,141,000 | $ (109,482,000) | $ 1,290,000 |
Balance, shares at Jul. 31, 2017 | 63,093,153 | |||
Share-based compensation expense - stock options | 1,525,000 | 1,525,000 | ||
Share-based compensation expense - restricted stock units | 834,000 | 834,000 | ||
Issuance of common stock upon exercise of warrants | $ 49,000 | 2,583,000 | 2,632,000 | |
Issuance of common stock upon exercise of warrants, shares | 4,914,505 | |||
Inducement to exercise warrants | 876,000 | 876,000 | ||
Warrant liability removed due to warrant exercise | 1,394,000 | 1,394,000 | ||
Stock issued for services | $ 3,000 | 169,000 | 172,000 | |
Stock issued for services, shares | 240,500 | |||
Net loss | (7,442,000) | (7,442,000) | ||
Balance at Jul. 31, 2018 | $ 683,000 | 117,522,000 | (116,924,000) | 1,281,000 |
Balance, shares at Jul. 31, 2018 | 68,248,158 | |||
Issuance of common stock in private placements, net | $ 58,000 | 2,156,000 | 2,214,000 | |
Issuance of common stock in private placements, net, shares | 5,802,927 | |||
Share-based compensation expense - stock options | 1,387,000 | 1,387,000 | ||
Share-based compensation expense - restricted stock units | 1,062,000 | 1,062,000 | ||
Issuance of common stock upon the vesting of restricted stock units | $ 3,000 | (3,000) | ||
Issuance of common stock upon the vesting of restricted stock units, shares | 281,250 | |||
Issuance of common stock upon exercise of warrants | $ 24,000 | 816,000 | 840,000 | |
Issuance of common stock upon exercise of warrants, shares | 2,399,999 | |||
Inducement to exercise warrants | 960,000 | 960,000 | ||
Net loss | (6,554,000) | (6,554,000) | ||
Balance at Jul. 31, 2019 | $ 768,000 | $ 123,900,000 | $ (123,478,000) | $ 1,190,000 |
Balance, shares at Jul. 31, 2019 | 76,732,334 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Operating activities | ||
Net loss | $ (6,554,000) | $ (7,442,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Share-based compensation | 2,449,000 | 2,359,000 |
Amortization of stock issued for services | 38,000 | 122,000 |
Stock issued for services | 121,000 | |
Depreciation and amortization | 241,000 | 285,000 |
Inventory write-off | 58,000 | |
Gain on inventory recovery | (19,000) | |
Interest expense on promissory note | 1,000 | 3,000 |
Change in fair value of derivative liability | (459,000) | |
Inducement to exercise warrants | 960,000 | 876,000 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (98,000) | 22,000 |
Inventories | 20,000 | 37,000 |
Prepaid expenses | 2,000 | 45,000 |
Accounts payable and accrued liabilities | (40,000) | 103,000 |
Deferred rent | (9,000) | 2,000 |
Net cash used in operating activities | (2,990,000) | (3,887,000) |
Investing activities | ||
Investment in patents | (6,000) | (15,000) |
Purchases of property, plant and equipment | (7,000) | (19,000) |
Net cash used in investing activities | (13,000) | (34,000) |
Financing activities | ||
Net proceeds from the sale of common stock | 1,710,000 | |
Net proceeds from the exercise of warrants | 840,000 | 2,632,000 |
Net proceeds from promissory note financing | 500,000 | |
Net cash provided by financing activities | 2,550,000 | 3,132,000 |
Net decrease in cash, cash equivalents, and restricted cash | (453,000) | (789,000) |
Cash, cash equivalents, and restricted cash at beginning of year | 926,000 | 1,715,000 |
Cash, cash equivalents, and restricted cash at end of year | 473,000 | 926,000 |
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets | ||
Cash and cash equivalents | 398,000 | 851,000 |
Restricted cash | 75,000 | 75,000 |
Total cash, cash equivalents and restricted cash | 473,000 | 926,000 |
Supplemental disclosure of cash flow information | ||
Cash paid for taxes | 5,000 | 3,000 |
Non-cash financing activities | ||
Warrant liabilities removed due to settlements | 1,394,000 | |
Common stock issued for prepaid services | 51,000 | |
Conversion of promissory note and accrued interest from a related party to common stock | $ 504,000 |
Organization and Business
Organization and Business | 12 Months Ended |
Jul. 31, 2019 | |
Accounting Policies [Abstract] | |
Organization and Business | 1. Organization and Business All references to “PURE,” “we”, “our,” and “us” refer to PURE Bioscience, Inc. and our wholly owned subsidiary. PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent that is manufactured as a liquid delivered in various concentrations. We currently distribute and contract the manufacture and distribution of our SDC-based disinfecting and sanitizing products. We also contract manufacture and sell SDC-based formulations to manufacturers for use as a raw material ingredient in the production of personal care products. We believe our technology platform has potential application in a number of industries. We intend to focus our current resources on providing food safety solutions to the food industry. We were incorporated in the state of California in August 1992 as Innovative Medical Services. In September 2003, we changed our name to PURE Bioscience. In March 2011, we reincorporated in the state of Delaware. We operate in one business segment. Liquidity & Going Concern Uncertainty Since our inception, we have financed our operations primarily through public and private offerings of securities, debt financing, and revenue from product sales and license agreements. We have a history of recurring losses, and as of July 31, 2019, we have incurred a cumulative net loss of $123,478,000. We do not have, and may never have, significant cash inflows from product sales or from other sources of revenue to fund our operations. As of July 31, 2019, we had $398,000 in cash and cash equivalents, and $738,000 of current liabilities, including $553,000 in accounts payable. On October 2, 2019, we entered into and completed a closing of a private placement financing to accredited investors. We raised net proceeds of $830,000 in the closing of an aggregate of 2,862,068 shares of the Company’s common stock at a purchase price of $0.29 per share. Tom Y. Lee and Dale Okuno, each of whom are accredited investors and members of the Company’s Board of Directors invested $290,000 and $250,000, respectively, in the private placement financing. Mr. Lee also serves as the Company’s President and Chief Executive Officer. Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources. Until we can generate significant cash from operations, we expect to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether. We do not have any unused credit facilities or other sources of capital available to us at this time. We intend to secure additional working capital through sales of additional debt or equity securities. Our intended financing initiatives are subject to risk, and we cannot provide any assurance about the availability or terms of these or any future financings. These consolidated financial statements have been prepared and presented on a basis assuming we will continue as a going concern. The factors above raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustment relating to recoverability or classification of recorded assets and classification of recorded liabilities. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Jul. 31, 2019 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETIH2O Inc., a Nevada corporation. ETIH2O Inc. has no business and no material assets or liabilities and there have been no significant transactions related to ETIH2O Inc. during the periods presented in the consolidated financial statements. All inter-company balances and transactions have been eliminated. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with original maturities from the purchase date of three months or less. Restricted Cash The Company is required to maintain $75,000 in a restricted certificate of deposit account in order to fully collateralize four revolving credit card accounts. Fair Value of Financial Instruments Certain of our financial instruments—including cash and cash equivalents, accounts receivable, inventories, prepaid expenses, accounts payable, accrued liabilities, and deferred rent are carried at cost, which is considered to be representative of their respective fair values because of the short-term nature of these instruments. Our derivative liabilities were carried at estimated fair value (See Notes 5 and 6 to these consolidated financial statements). Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates of allowances for doubtful accounts are determined based on historical payment patterns and individual customer circumstances. The allowance for doubtful accounts was zero at July 31, 2019 and 2018. Inventories Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of our property, plant, and equipment range from three to ten years. Capitalized costs associated with leasehold improvements are depreciated over the lesser of the useful life of the asset or the remaining life of the lease. Depreciation is generally included in selling, general and administrative expense. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold. Patents We have filed a number of patent applications with the United States Patent and Trademark Office and in foreign countries. Certain legal and related costs incurred in connection with pending patent applications have been capitalized. Costs related to successful patent applications are amortized over the lesser of the remaining useful life of the related technology or the remaining patent life, commencing on the date the patent is issued. Capitalized costs related to patent applications are expensed in the period in which a determination is made not to pursue such applications. Impairment of Long-Lived Assets In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. There were no patent impairments during the years ended July 31, 2019 or 2018. Revenue Recognition Effective August 1, 2018, we adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process: 1. Identify the contract with the customer 2. Identify the performance obligations in the contract 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations in the contract 5. Recognize revenue when (or as) each performance obligation is satisfied Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control® as a direct food contact processing aid. Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price. Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Our direct customer and distributer sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns. Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales. We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. Variable Consideration We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur. Practical Expedient We elected a practical expedient to expense sales commissions when the commissions are incurred because the amortization period would have been one year or less. These costs are recorded as Selling, general and administrative expense on our Consolidated Statements of Operations. Shipping and Handling Costs Shipping and handling costs incurred by us for product shipments are included in cost of goods sold and were minimal for the years ended July 31, 2019 and 2018. Research and Development Costs Research and development costs are expensed as incurred. Share-Based Compensation We grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Comprehensive Loss Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments. For the years ended July 31, 2019 and 2018, our comprehensive loss consisted only of net loss. Income Taxes We recognize deferred tax assets and liabilities for temporary differences between the tax basis of assets and liabilities and the amounts at which they are carried in the financial statements based upon the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established to reduce deferred tax assets to the amount expected to be realized. Net Loss Per Share Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an antidilutive effect. For the years ended July 31, 2019 and 2018, the number of shares issuable upon the exercise of stock options, the vesting of restricted stock units, and the exercise of warrants, none of which are included in the computation of basic net loss per common share, was 9,736,722 and 12,012,189, respectively. Recent Accounting Pronouncements In May 2014, the FASB issued Topic 606, which supersedes most existing revenue recognition guidance in U.S. generally accepted accounting principles (“GAAP”), including most industry-specific guidance. The standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The new standard was originally effective for public companies for annual reporting periods beginning after December 15, 2016, with no early application permitted. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers, which deferred by one year the effective date for all entities, with application permitted as of the original effective date. The standard allows for either a full retrospective or modified retrospective method of adoption. We adopted the new standard for the fiscal year beginning August 1, 2018 using the modified retrospective application method. Under this method, entities recognize the cumulative impact of applying the new standard at the date of adoption without restatement of prior periods presented. The cumulative effect of applying the new standard to contracts that were not completed as of August 1, 2018 did not have a material impact on our consolidated financial position, results of operations, or cash flows. The new standard also requires enhanced disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. Topic 606 supersedes the revenue recognition requirements in ASC Topic 605, Revenue Recognition (“Topic 605”). While results for reporting periods beginning after August 1, 2018 are presented under Topic 606, all prior period amounts are not adjusted and continue to be reported under the accounting standards in effect during these prior periods. The accounting policies for revenue recognition for periods prior to August 1, 2018 are described in “Note 2. Summary of Significant Accounting Policies” of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended July 31, 2018. Adoption of this ASC did not have a material impact on our consolidated financial statements. Refer to the revenue recognition disclosure above. In July 2017, the Financial Accounting Standards Board (“FASB”) issued a two-part Accounting Standards Update (“ASU”) No. 2017-11, I. Accounting for Certain Financial Instruments With Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception (“ASU 2017-11”). ASU 2017-11 amends guidance in FASB ASC 260, Earnings Per Share, FASB ASC 480, Distinguishing Liabilities from Equity, and FASB ASC 815, Derivatives and Hedging. The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 with early adoption permitted. The adoption of this guidance had no impact on our financial statements as all derivative liabilities were all exercised or expired as of July 31, 2018. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The standard clarifies the presentation of restricted cash and cash equivalents and requires companies to include restricted cash and cash equivalents in the beginning and ending balances of cash and cash equivalents on the statement of cash flows. The standard also requires additional disclosures to describe the amount and detail of the restriction by balance sheet line item. The new standard was effective for us on August 1, 2018. We adopted this standard using the retrospective transition method by restating the consolidated statements of cash flows to include restricted cash of $75,000 in the beginning and ending cash, cash equivalents, and restricted cash balance. Net cash flows for the fiscal year ended July 31, 2018, did not change as a result of including restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts presented on the statements of cash flows. In December 2017, the United States (“U.S.”) enacted the Tax Cuts and Jobs Act (the “2017 Act”), which changes existing U.S. tax law and includes various provisions that are expected to affect public companies. The 2017 Act (i) changes U.S. corporate tax rates, (ii) generally reduces a company’s ability to utilize accumulated net operating losses, and (iii) requires the calculation of a one-time transition tax on certain previously unrepatriated foreign earnings and profits (“E&P”). The 2017 Act will also impact estimates of a company’s deferred tax assets and liabilities. On December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed in reasonable detail to complete the accounting for certain income tax effects of the Tax Cuts and Jobs Act (“U.S. Tax Cuts and Jobs Act of 2017”). This new law did not have a significant impact on our consolidated financial statements for the years ended July 31, 2019 and 2018 because we maintain a valuation allowance on the entirety of our deferred tax assets. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which provides clarity and guidance around which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting. The new standard was effective for annual reporting periods beginning after April 1, 2018, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting, which aligns the measurement and classification guidance for share-based payment to non-employees with the guidance for share-based payments to employees. Under the new guidance, the measurement period for equity-classified non-employee awards will be fixed at the grant date. This update is effective for annual periods beginning after December 15, 2018, and interim periods within those periods and early adoption is permitted. We elected to early adopt ASU No. 2018-07 during the fiscal year ended July 31, 2019. The adoption of this guidance had no material impact on our financial statements. |
Balance Sheet Details
Balance Sheet Details | 12 Months Ended |
Jul. 31, 2019 | |
Balance Sheet Related Disclosures [Abstract] | |
Balance Sheet Details | 3. Balance Sheet Details Inventories consist of the following: July 31, 2019 2018 Raw materials $ 30,000 $ 39,000 Finished goods 147,000 158,000 $ 177,000 $ 197,000 During the year ended July 31, 2018, we wrote-off $58,000 of finished goods inventory damaged at our contract manufacturer’s facility. In addition we wrote-off $26,000 of inventory destroyed in a third-party warehouse fire. We received $45,000 from an insurance claim for the replacement cost of the inventory destroyed in the fire. As a result, we recorded a gain of $19,000 reflected in the other income section of our consolidated statements of operations. Property, plant, and equipment consist of the following: July 31, 2019 2018 Computers and equipment $ 1,001,000 $ 1,064,000 Furniture and fixtures 21,000 21,000 1,022,000 1,085,000 Less accumulated depreciation (660,000 ) (624,000 ) $ 362,000 $ 461,000 Depreciation expense remained unchanged at $106,000 for the years ended July 31, 2019 and 2018, respectively. Patents consist of the following: July 31, 2019 2018 Patents $ 3,504,000 $ 3,500,000 Less accumulated amortization (2,975,000 ) (2,842,000 ) $ 529,000 $ 658,000 Patent amortization expense for the years ended July 31, 2019 and 2018 was $135,000 and $179,000, respectively. At July 31, 2019, future patent amortization expense is expected to be as follows: 2020 $ 87,000 2021 76,000 2022 48,000 2023 42,000 2024 42,000 Thereafter 234,000 $ 529,000 |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Jul. 31, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 4. Commitments and Contingencies Legal From time to time, we could become involved in disputes and various litigation matters that arise in the normal course of business. Lawsuits against us or our officers or directors by employees, former employees, stockholders, partners, customers, or others, or actions taken by regulatory authorities, could be very costly and substantially disrupt our business. Such lawsuits and actions are not uncommon, and we may not be able to resolve such disputes or actions on terms favorable to us, and there may not be sufficient capital resources available to defend such actions effectively, or at all. As of July 31, 2019, there were no material lawsuits against the Company. Operating Leases During August 2016, we amended the lease of our primary facility in El Cajon, California under a noncancelable operating lease that now expires in December 2019. This facility includes our corporate offices, research and development laboratory, and warehouse. Rent expense, including common area maintenance, was $111,000 and $121,000 for the years ended July 31, 2019 and 2018, respectively. On July 29, 2019, we entered into a Sublease Agreement (the “Sublease”) with SwabPlus L.P. (“SwabPlus”), effective July 25, 2019, pursuant to which we will sublease certain office and industrial space for our corporate headquarters. The premises are located in Rancho Cucamonga, California. Pursuant to the terms of the Sublease, the Company will pay SwabPlus rent of approximately $2,333 per month, plus additional payments for real property taxes, maintenance and repair and related expenses. We terminated the El Cajon lease and transitioned to the new premises in September 2019. We expect the Sublease to drastically reduce our operating expenses as compared to our operating expenses under our prior lease at the El Cajon facility. Tom Y. Lee, the Company’s Chief Executive Officer, Chairman of the Board and President, also serves as chairman of the board of directors and chief executive officer of SwabPlus. Mr. Lee also serves as president of Hermosa Property, Inc., the landlord of the premises subject to the Sublease. The Sublease was considered by the Company in accordance with the Company’s Related Party Transaction and Procedures Policy, and approved by the disinterested members of the Board. Future minimum annual lease payments for our primary facility as of July 31, 2019 are as follows: 2019 $ 37,000 2020 $ 14,000 $ 51,000 |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 12 Months Ended |
Jul. 31, 2019 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | 5 Fair Value of Financial Instruments Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows: ● Level 1 – Quoted prices in active markets for identical assets or liabilities. ● Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. In connection with the October and November 2015 Private Placements, we issued warrants with derivative features. These instruments were accounted for as derivative liabilities (See Note 6 to these consolidated financial statements). We used Level 3 inputs for the valuation methodology of the derivative liabilities. The estimated fair values were computed using a Monte Carlo option pricing model based on various assumptions. Our derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of the derivative liabilities. Various factors are considered in the pricing models we use to value the warrants, including the Company’s current stock price, the remaining life of the warrants, the volatility of the Company’s stock price, and the risk free interest rate. The following table provides a reconciliation of the beginning and ending balances of the derivative liabilities for the year ended July 31, 2018: Fair Value of Significant Unobservable Inputs (Level 3) Warrant Liability Balance at July 31, 2017 $ 1,853,000 Issuances — Settlement of warrant liability (1,394,000 ) Adjustments to estimated fair value (459,000 ) Balance at July 31, 2018 $ — |
Derivative Liability
Derivative Liability | 12 Months Ended |
Jul. 31, 2019 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Liability | 6. Derivative Liability During October and November of 2015 we closed two private placement financings (the “2015 Private Placement Financing”) and issued 20,376,219 warrants. We accounted for warrants issued in connection with the 2015 Private Placement Financing in accordance with the accounting guidance for derivatives. The applicable accounting guidance sets forth a two-step model to be applied in determining whether a financial instrument is indexed to an entity’s own stock, which would qualify such financial instruments for a scope exception. This scope exception specifies that a contract that would otherwise meet the definition of a derivative financial instrument would not be considered as such if the contract is both (i) indexed to the entity’s own stock and (ii) classified in the stockholders’ equity section of the entity’s balance sheet. We determined the warrants were ineligible for equity classification due to anti-dilution provisions set forth therein. On September 25, 2017, we completed the first closing of a tender offer to amend and exercise outstanding warrants to purchase shares of our common stock. As a result, 1,599,135 warrants issued in connection with the 2015 Private Placement Financing were exercised. In addition, there was a net exercise on 118,057 warrants which resulted in the issuance of 63,811 shares of our common stock. The change in fair value of the warrant liabilities on September 25, 2017 was recorded as a change in derivative liabilities in the consolidated statements of operations during the fiscal year ended July 31, 2018. In addition, the fair value on the exercise date was returned to additional paid in capital. On October 10, 2017, we completed a second and final closing of a tender offer to amend and exercise outstanding warrants to purchase shares of our common stock. As a result, 268,909 warrants issued in connection with the 2015 Private Placement Financing were exercised. The change in fair value of the warrant liabilities on October 10, 2017 was recorded as a change in derivative liabilities in the consolidated statements of operations during the fiscal year ended July 31, 2018. In addition, the fair value on the exercise date was returned to additional paid in capital. During the fiscal year ended July 31, 2018, all outstanding warrants containing derivative features issued in connection with the 2015 Private Placement Financing were exercised. The change in fair value of the warrant liabilities for the fiscal year ended July 31, 2018, was a decrease of $459,000, which was recorded as a change in derivative liabilities in the consolidated statements of operations. As of July 31, 2019, there were no warrants classified as derivatives outstanding. |
Promissory Note Payable
Promissory Note Payable | 12 Months Ended |
Jul. 31, 2019 | |
Debt Disclosure [Abstract] | |
Promissory Note Payable | 7. Promissory Note Payable On June 28, 2018, we raised $500,000 to support our continued operations by issuing a one-year promissory note to Tom Y. Lee, a member of the Company’s Board of Directors and our largest stockholder. The note accrued interest at 6.5% per annum, compounded annually. On August 16, 2018, $500,000 of principal and approximately $4,000 of accrued interest was converted into 1,120,633 shares of common stock (See Note 8 to these consolidated financial statements). |
Stockholders' Equity
Stockholders' Equity | 12 Months Ended |
Jul. 31, 2019 | |
Stockholders' equity | |
Stockholders' Equity | 8. Stockholders’ Equity Preferred Stock As of July 31, 2019, the Company’s Board of Directors is authorized to issue 5,000,000 shares of preferred stock with a par value of $0.01 per share, in one or more series. As of July 31, 2019 and July 31, 2018, there were no shares of preferred stock issued and outstanding. Common Stock As of July 31, 2019, 100,000,000 shares of common stock with a par value of $0.01 per share are authorized for issuance. Private Placement Financing On August 16, 2018, we completed a closing (the “Closing”) of a private placement financing to accredited investors. We raised approximately $1.5 million in the Closing and issued an aggregate of 3,333,964 shares of our common stock at a purchase price of $0.45 per share, including the conversion of approximately $0.5 million held in the form of a promissory note as of July 31, 2018. The shares issued in the private placement financing were issued pursuant to a securities purchase agreement entered into with the investors. Mr. Tom Y. Lee, a member of the Company’s Board of Directors invested approximately $1.0 million through his affiliates, including approximately $0.5 million of cash and the conversion of existing indebtedness in the amount of approximately $0.5 million that was held in the form of a promissory note payable as of July 31, 2018. The net proceeds to us from the Closing (including the conversion of indebtedness), after deducting fees and other offering expenses, were approximately $1.5 million. The issuance and sale of the shares was not registered under the Securities Act of 1933, as amended (the “Securities Act”), and these shares may not be offered or sold in the United States absent registration under or exemption from the Securities Act and any applicable state securities laws. The shares were issued and sold in reliance upon an exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act. The Investors represented to the Company that each was an “accredited investor” within the meaning of Rule 501 of Regulation D under the Securities Act, and that each was receiving the shares for investment for its own account and without a view to distribute them. On February 19, 2019, we entered into warrants amendments (each a “Warrant Amendment”, and together, the “Warrant Amendments”) with three holders of warrants to purchase the Company’s common stock issued in August 2014 (the “2014 Warrants”). The Warrant Amendments provided (i) for a reduction in the exercise price from $0.75 to $0.35 and (ii) that 2014 Warrants would expire unless otherwise exercised on the date of the Warrant Amendments. In connection with the execution of the Warrant Amendments, on February 19, 2019, the holders exercised the 2014 Warrants to purchase 2,399,999 shares of common stock for an aggregate exercise price of $840,000. Tom Lee, the Company’s Chairman of the Board, and beneficial holder of a 2014 Warrant to purchase 2,133,333 shares of Common Stock, entered into a Warrant Amendment and exercised his 2014 Warrant for an aggregate exercise price of $746,666. Additionally, Dale Okuno, a member of the Company’s Board of Directors, and beneficial holder of a 2014 Warrant to purchase 213,333 shares of Common Stock, entered into a Warrant Amendment and exercised his 2014 Warrant for an aggregate exercise price of $74,666. Due to the reduction in exercise price for the 2014 Warrants issued in connection with the Warrant Amendment, we determined it was appropriate to record $960,000 of expense in the 2019 consolidated statement of operations for the inducement to exercise the 2014 Warrants. During May, June and July of 2019, we completed three closings (the “Closings”) of a private placement financings to accredited investors. We raised net proceeds of $716,000 in the Closings and issued an aggregate of 2,468,963 shares of our common stock at a purchase price of $0.29 per share. The shares issued in the private placement financing were issued pursuant to a securities purchase agreement entered into with the investors. Messrs. Dale Okuno and Ivan Chen, each of whom are accredited investors and members of the Company’s Board of Directors invested $250,000 and $35,000, respectively, in the private placement financings. The net proceeds to us from the Closings, after deducting fees and other offering expenses, were approximately $716,000. We expect to use the net proceeds for general corporate purposes, including our research and development efforts, and for general administrative expenses and working capital. The issuance and sale of the shares was not registered under the Securities Act of 1933, as amended (the “Securities Act”), and these shares may not be offered or sold in the United States absent registration under or exemption from the Securities Act and any applicable state securities laws. The shares were issued and sold in reliance upon an exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act. The Investors represented to the Company that each was an “accredited investor” within the meaning of Rule 501 of Regulation D under the Securities Act, and that each was receiving the shares for investment for its own account and without a view to distribute them. Schedule TO and Warrant Exercises On October 10, 2017, we closed the offer to amend and exercise outstanding warrants to purchase shares of our common stock (the “Tender Offer”). Specifically, we filed a Schedule TO with the SEC on August 25, 2017 offering to (i) reduce the exercise price of the warrants to purchase 4,104,980 shares of common stock issued to investors participating in our private placement financing completed on August 29, 2014, as amended (the “2014 Warrants”) from $0.75 per share to $0.60 per share of common stock in cash, (ii) reduce the exercise price of outstanding warrants to purchase 1,986,101 shares of common stock issued to investors participating in our private placement financing completed on November 23, 2015 (the “2015 Warrants”) from $0.45 per share to $0.40 per share of common stock in cash, (iii) reduce the exercise price of the outstanding warrants to purchase 1,572,941 shares of common stock issued to investors participating in our private placement financing completed on January 23, 2017 (the “2017 Warrants”, together with the 2014 Warrants and 2015 Warrants, the “Original Warrants”) from $1.25 per share to $0.85 per share of common stock in cash, (iv) shorten the exercise period of the Original Warrants so that they expired concurrently with the expiration of the Offer to Amend and Exercise at 5:00 p.m. (Pacific Time) on September 25, 2017 (“Expiration Date”) unless extended until the Subsequent Expiration Date (as defined below), (v) delete the cashless exercise provisions in the Original Warrants and (vi) delete the price-based anti-dilution provisions contained in the 2015 Warrants. Additionally, we requested the holders of a majority of the shares issuable upon exercise of the 2014 Warrants (the “2014 Requisite Majority”), 2015 Warrants (the “2015 Requisite Majority”) and 2017 Warrants (the “2017 Requisite Majority”) to approve an amendment of all of the outstanding 2014 Warrants, 2015 Warrants and 2017 Warrants, respectively, to amend such Original Warrants in the same manner as set forth above (the “Aggregate Warrant Amendment”), except the Expiration Date would be extended until October 10, 2017 (the “Subsequent Expiration Date”) if such Aggregate Warrant Amendment was approved with respect to such class of Original Warrants. The 2015 Requisite Majority approved an amendment of all of the outstanding 2015 Warrants and holders of 2015 Warrants had until the Subsequent Expiration Date to exercise their 2015 Warrants (the “Subsequent Offer Period”). The Offer to Amend and Exercise with respect to the 2014 Warrants and 2017 Warrants expired on the Expiration Date of September 25, 2017. As of September 25, 2017, 1,491,649 shares of common stock were issued upon exercise of 2014 Warrants, 1,599,135 shares of common stock were issued upon exercise of 2015 Warrants and 1,396,470 shares of common stock were issued upon exercise of 2017 Warrants, for aggregate gross proceeds to us of approximately $2,720,000. During the Subsequent Offer Period, 2015 Warrants to purchase 268,909 shares of common stock were exercised for aggregate gross proceeds to us of approximately $107,000. 2014 Warrants to purchase 2,533,331 shares of common stock and 2017 Warrants to purchase 176,471 shares of common stock at exercise prices of $0.75 per share and $1.25 per share, respectively, continue to remain outstanding and no 2015 Warrants remain outstanding. Original Warrants (including 2015 Warrants exercised during the Subsequent Offer Period) to purchase an aggregate of 4,756,163 shares of common stock were tendered and exercised in the Offer to Amend and Exercise for aggregate net proceeds to us of approximately $2,632,000. Garden State Securities Inc. assisted the Company as warrant solicitation agents with respect to the 2017 Warrants. Due to the reduction in exercise price for the Original Warrants issued in connection with the Schedule TO, we determined it was appropriate to record $876,000 of expense in the 2018 consolidated statement of operations for the inducement to exercise the Original Warrants. Other Activity During the three months ended October 31, 2017, we entered into a two-year service agreement for business development services. In accordance with the agreement we issued 50,000 shares of common stock, with a value of $51,000. The value was capitalized to prepaid expense and is being amortized over the term of the agreement. During the fiscal year ended July 31, 2019 and 2018, we recognized $25,000 and $21,000 of expense related to these services, respectively. On April 13, 2016, we entered into a two-year service agreement for general financial advisory services. In accordance with the agreement we issued 250,000 shares of common stock, with a value of $290,000. The value was capitalized to prepaid expense and was being amortized over the term of the agreement. During the fiscal year ended July 31, 2018, we recognized $101,000 of expense related to these services. Additional Warrant Exercise During the fiscal year ended July 31, 2018, there was a net exercise on 573,057 warrants which resulted in the issuance of 158,342 shares of our common stock. As these warrants were net exercised, as permitted under the respective warrant agreement, we did not receive any cash proceeds. 198,057 of the warrants exercised during the period were issued in connection with the Original Warrants discussed above. A summary of our warrant activity and related data is as follows: Shares Outstanding at July 31, 2017 8,303,836 Issued — Exercised (5,329,220 ) Expired/Cancelled (113,520 ) Outstanding at July 31, 2018 2,861,096 Issued — Exercised (2,399,999 ) Expired/Cancelled — Outstanding at July 31, 2019 461,097 The following table summarizes information related to warrants outstanding at July 31, 2019: Expiration Exercise Date Price Shares 08/29/19 $ 0.75 133,332 12/01/21 $ 1.25 58,824 12/01/21 $ 1.28 117,647 01/23/22 $ 1.25 117,647 01/23/22 $ 1.28 33,647 461,097 |
Share-Based Compensation
Share-Based Compensation | 12 Months Ended |
Jul. 31, 2019 | |
Share-based Payment Arrangement [Abstract] | |
Share-Based Compensation | 9. Share-Based Compensation Restricted Stock Units During the fiscal year ended July 31, 2019, the Compensation Committee of the Board of Directors authorized the issuance of 725,000 Restricted Stock Units (“RSUs”) to officers and consultants. The RSUs vest over a two year period and carry a ten year term. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement. On October 4, 2018, the Board of Directors appointed Tom Myers as the Company’s Chief Operating Officer. In connection with Mr. Myer’s appointment, the Board agreed to grant him 500,000 RSUs upon the achievement by the Company of cash flow breakeven for a fiscal quarter, after which such RSUs shall vest annually over the following three years. Based on the applicable guidance, we determined that these RSUs are not deemed to be granted and therefore there are no accounting implications as of July 31, 2019. During the fiscal year ended July 31, 2018, the Compensation Committee of the Board of Directors authorized the issuance of 450,000 RSUs to newly appointed members of our Board of Directors. RSUs issued to directors vest in two 50% installments on or before our annual meeting of stockholders, typically held in January. In addition, we issued 300,000 performance based RSUs to third-party consultants. We currently do not expect the 300,000 RSUs to vest. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU is delivered and subsequently settles, as set forth in the Restricted Stock Unit Agreement. A summary of our restricted stock unit activity and related data is as follows: Shares Outstanding at July 31, 2017 2,035,000 Granted 750,000 Vested (375,000 ) Forfeited (885,000 ) Outstanding at July 31, 2018 1,525,000 Granted 725,000 Vested (206,250 ) Forfeited (131,250 ) Outstanding at July 31, 2019 1,912,500 Of the 1,912,500 RSUs outstanding, we currently expect 456,250 to vest. As of July 31, 2019, there was $207,000 of unrecognized non-cash compensation cost related to RSUs we expect to vest, which will be recognized over a weighted average period of 1.80 years. Of the 1,912,500 RSUs outstanding as of July 31, 2019, 1,456,250 RSUs are vested and the underlying common stock has not been delivered and remains outstanding, as set forth in the RSU agreements. For the fiscal year ended July 31, 2019 share-based compensation expense for RSUs was $1,062,000, of which $489,000 was due to the accelerated vesting of RSU’s held by Dave Pfanzelter, the former Chairman of our Board. Mr. Pfanzelter retired from our Board in August 2018. For the fiscal year ended July 31, 2018 share-based compensation expense for RSUs was $834,000. Stock Option Plans 2007 Equity Incentive Plan In February 2016, we amended and restated our 2007 Equity Incentive Plan, the (“2007 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2007 Plan by 4,000,000 shares and extend the term of the 2007 Plan until February 4, 2026. The 2007 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of July 31, 2019, there were approximately 1,153,000 shares available for issuance under the 2007 Plan. 2017 Equity Incentive Plan Our shareholders approved our 2017 Equity Incentive Plan (the “2017 Plan”) in January 2018, which has a share reserve of 5,000,000 shares of common stock that were registered under a Form S-8 filed with the SEC in February 2018. The 2017 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of July 31, 2019, there were approximately 2,071,000 shares available for issuance under the 2017 Plan. Stock Option Activity During the fiscal year ended July 31, 2019, the Compensation Committee of the Board of Directors authorized the issuance of 200,000 stock options to a newly appointed member of our board of directors. The options vest over a two year period and carry a ten year term. In addition, during the fiscal year ended July 31, 2019, the Compensation Committee of the Board of Directors authorized the issuance of 100,000 stock options to a consultant supporting our business development activities. The options vest monthly over a two year period and carry a five year term. During the fiscal year ended July 31, 2018, we issued 2,245,000 stock options at various exercise prices to employees, directors, and consultants. The options vest between one and two years and carry a term between five and ten years. During the fiscal year ended July 31, 2018, the Compensation Committee of the Board of Directors extended the expiration terms of 740,000 employee options by three years. We accounted for the option modification under ASC Topic 718 and recorded a one-time expense of $203,000, which was expensed under the share-based compensation line item on the consolidated statements of operations. A summary of our stock option activity for the fiscal years ended July 31, 2019 and 2018 is as follows: Shares Weighted- Aggregate Outstanding at July 31, 2017 5,759,843 $ 1.25 $ 1,120,000 Granted 2,245,000 $ — Exercised — $ — Cancelled (378,750 ) $ 1.96 Outstanding at July 31, 2018 7,626,093 $ 1.09 $ — Granted 300,000 $ 0.52 Exercised — $ — Cancelled (562,968 ) $ 1.47 Outstanding at July 31, 2019 7,363,125 $ 1.04 $ — The weighted average expected term of options outstanding at July 31, 2019 was 4.60 years. At July 31, 2019, options to purchase 6,354,792 shares of common stock were exercisable. These options had a weighted-average exercise price of $1.04, an aggregate intrinsic value of zero, and a weighted average expected term of 4.32 years. The weighted average grant date fair value for options granted during the years ended July 31, 2019 and 2018, was $0.52 and $0.44, respectively. The total unrecognized compensation cost related to unvested stock option grants as of July 31, 2019 was approximately $312,000 and the weighted average period over which these grants are expected to vest is 1.88 years. For the fiscal year ended July 31, 2019 and 2018, share-based compensation expense for stock options was $1,387,000 and $1,525,000 respectively. We use the Black-Scholes valuation model to calculate the fair value of stock options. Share-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions: For the years ended July 31, 2019 2018 Volatility 75.67 % 71.18 % Risk-free interest rate 2.63 % 2.32 % Dividend yield 0.0 % 0.0 % Expected life 4.80 years 3.69 years Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. Certain options granted to consultants are subject to variable accounting treatment and are required to be revalued until vested. |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Jul. 31, 2019 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 10. Related Party Transactions On June 28, 2018, we raised $500,000 to support our continued operations by issuing a one-year promissory note to Tom Y. Lee, a member of the Company’s Board of Directors and our largest stockholder. The note accrued interest at 6.5% per annum, compounded annually. On August 16, 2018, $500,000 of principal and approximately $4,000 of accrued interest was converted into 1,120,633 shares of common stock (See Note 8 to these consolidated financial statements). On June 9, 2019, we entered into a five-year manufacturing supply agreement with Intercon Chemical Company (ICC) with a three-year renewal term option (the “Manufacturing Supply Agreement”). The agreement consists of manufacturing, packaging, and distribution of PURE’s SDC-based products. The Manufacturing Supply Agreement provides: ● ICC licenses PURE’s patents and technology know-how for the non-exclusive manufacture of PURE’s SDC-based products. ● ICC will invest in plant improvements to allow for expanded SDC production. ● ICC’s R&D team will collaborate on SDC product line development. The Manufacturing Supply Agreement may be terminated by mutual written consent, or by either party upon the material breach of the terms of the agreement by the other party. During the years ended July 31, 2019 and 2018, our net product sales to ICC was $5,000 and $8,000, respectively. As of July 31, 2019 and 2018, there was no accounts receivable due to the Company for products purchased by ICC. During the years ended July 31, 2019 and 2018, we purchased $540,000 and $575,000, of SDC based products produced by ICC, respectively. Additionally, as of July 31, 2019 and 2018, $65,000 and $85,000 was payable to ICC for the production of SDC based products, respectively. The president of ICC is a shareholder of the Company. On July 29, 2019, we entered into a Sublease Agreement (the “Sublease”) with SwabPlus L.P. (“SwabPlus”), effective July 25, 2019, pursuant to which we will sublease certain office and industrial space for our corporate headquarters. The premises are located in Rancho Cucamonga, California. Pursuant to the terms of the Sublease, the Company will pay SwabPlus rent of approximately $2,333 per month, plus additional payments for real property taxes, maintenance and repair and related expenses. We terminated the El Cajon lease and transitioned to the new premises in September 2019. We expect the Sublease to drastically reduce our operating expenses as compared to our operating expenses under our prior lease at the El Cajon facility (See Note 4 to these consolidated financial statements). Tom Y. Lee, the Company’s Chief Executive Officer, Chairman of the Board and President, also serves as chairman of the board of directors and chief executive officer of SwabPlus. Mr. Lee also serves as president of Hermosa Property, Inc., the landlord of the premises subject to the Sublease. The Sublease was considered by the Company in accordance with the Company’s Related Party Transaction and Procedures Policy, and approved by the disinterested members of the Board. |
Sales Concentration
Sales Concentration | 12 Months Ended |
Jul. 31, 2019 | |
Risks and Uncertainties [Abstract] | |
Sales Concentration | 11. Sales Concentration Net product sales were $1,909,000 and $1,774,000 for the years ended July 31, 2019 and 2018, respectively. For the year ended July 31, 2019, one individual customer accounted for 15%, and two individual customers accounted for 11% of our net product sales. No other individual customer accounted for 10% or more of our net product sales. For the year ended July 31, 2018, three individual customers accounted for 20%, 16% and 11%, of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. For the years ended July 31, 2018 and 2017, all net product sales occurred in the United States. |
Income Taxes
Income Taxes | 12 Months Ended |
Jul. 31, 2019 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 12. Income Taxes We file federal and state consolidated tax returns with our subsidiaries. Our income tax provision for the years ended July 31, 2019 and 2018 was $1,650; the minimum state franchise taxes we pay regardless of income or loss. At July 31, 2019, we had federal and state tax net operating loss carry-forwards of approximately $108.3 million and $62.1 million, respectively. At July 31, 2018, we had federal and state tax net operating loss carry-forwards of approximately $105.2 million and $60.5 million, respectively. Utilization of the net operating loss carry-forwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code as well as similar state provisions. These ownership changes may limit the amount of net operating loss carry-forwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382 of the Internal Revenue Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Since our formation, we have raised capital through the issuance of capital stock on several occasions (both before and after our initial public offering in 1996) which, combined with the purchasing stockholders’ subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition. While we do not believe that we have experienced an ownership change, the pertinent tax rules related thereto are complex and subject to varying interpretations, and thus complete assurance cannot be provided that the taxing authorities would not take an alternative position. Our current federal tax loss carry-forwards begin expiring in the year ended July 31, 2020 and, unless previously utilized, all but $3.1 million will completely expire in the year ending July 31, 2038. The $3.1 million can be carried forward indefinitely. Our state tax loss carry-forwards began to expire in the year ending July 31, 2029, and will completely expire in the year ending July 31, 2039. Significant components of our deferred tax assets are as follows: July 31, 2019 2018 Net operating loss carry-forward $ 26,940,000 $ 26,170,000 Stock options and warrants 2,030,000 2,590,000 Other temporary differences (130,000 ) (130,000 ) Total deferred tax assets 28,840,000 28,630,000 Valuation allowance for deferred tax assets (28,840,000 ) (28,630,000 ) Net deferred tax assets $ — $ — A reconciliation of income taxes computed using the statutory income tax rate, compared to the effective tax rate, is as follows: 2019 2018 Federal tax benefit at the expected statutory rate 21.0 % 26.4 % State income tax, net of federal tax benefit 0.6 32.5 Expired net operating loss carryforwards — (20.0 ) Other (18.3 ) (2.9 ) Rate change adjustment — (175.4 ) Change in state tax rates — — Permanent items — — Valuation allowance (3.3 ) 139.4 Income tax benefit - effective rate 0.0 % 0.0 % Following authoritative guidance, we recognize the tax benefit from a tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense; however we have had no accrued interest or penalties at either July 31, 2019 or July 31, 2018. We are subject to income taxes in the United States and in various states, and our historical tax years remain subject to future examination by the U.S. and state tax authorities. During the years ended July 31, 2019 and 2018, we did not record any activity related to our unrecognized tax benefits. The Company and its subsidiaries are subject to federal income tax as well as income tax of multiple state jurisdictions. With few exceptions, the Company is no longer subject to income tax examination by tax authorities in major jurisdictions for tax years prior to 2012. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the carryforwards. The Company is not currently under examination by the IRS or state taxing authorities. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Jul. 31, 2019 | |
Subsequent Events [Abstract] | |
Subsequent Events | 13. Subsequent Events Private Placement Financing On October 2, 2019, we entered into and completed a closing (the “Closing”) of a private placement financing (the “Private Placement Financing”) to accredited investors. We raised net proceeds of $830,000 in the Closing of an aggregate of 2,862,068 shares (collectively, the “Shares”) of the Company’s common stock (the “Common Stock”) at a purchase price of $0.29 per share, the closing sales price of the Company’s common stock on the date prior to the Closing. The Shares issued in the Private Placement Financing were issued pursuant to a Securities Purchase Agreement (the “Securities Purchase Agreement”) entered into with the investors. Tom Y. Lee and Dale Okuno, each of whom are accredited investors and members of the Company’s Board of Directors (the “Board”) invested $290,000 and $250,000, respectively, in the Private Placement Financing. Mr. Lee also serves as the Company’s President and Chief Executive Officer. The net proceeds to the Company from the Closing, after deducting the forgoing fees and other offering expenses, are expected to be approximately $829,000. The Company expects to use the net proceeds for general corporate purposes, including the Company’s research and development efforts, and for g eneral administrative expenses and working capital The issuance and sale of the Shares was not registered under the Securities Act of 1933, as amended (the “Securities Act”), and these Shares may not be offered or sold in the United States absent registration under or exemption from the Securities Act and any applicable state securities laws. The Shares were issued and sold in reliance upon an exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act. The Investors represented to the Company that each was an “accredited investor” within the meaning of Rule 501 of Regulation D under the Securities Act, and that each was receiving the Shares for investment for its own account and without a view to distribute them. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Jul. 31, 2019 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETIH2O Inc., a Nevada corporation. ETIH2O Inc. has no business and no material assets or liabilities and there have been no significant transactions related to ETIH2O Inc. during the periods presented in the consolidated financial statements. All inter-company balances and transactions have been eliminated. |
Use of Estimates | Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. |
Cash and Cash Equivalents | Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid investments with original maturities from the purchase date of three months or less. |
Restricted Cash | Restricted Cash The Company is required to maintain $75,000 in a restricted certificate of deposit account in order to fully collateralize four revolving credit card accounts. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments Certain of our financial instruments—including cash and cash equivalents, accounts receivable, inventories, prepaid expenses, accounts payable, accrued liabilities, and deferred rent are carried at cost, which is considered to be representative of their respective fair values because of the short-term nature of these instruments. Our derivative liabilities were carried at estimated fair value (See Notes 5 and 6 to these consolidated financial statements). |
Accounts Receivable | Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates of allowances for doubtful accounts are determined based on historical payment patterns and individual customer circumstances. The allowance for doubtful accounts was zero at July 31, 2019 and 2018. |
Inventories | Inventories Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. |
Property, Plant and Equipment | Property, Plant and Equipment Property, plant and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of our property, plant, and equipment range from three to ten years. Capitalized costs associated with leasehold improvements are depreciated over the lesser of the useful life of the asset or the remaining life of the lease. Depreciation is generally included in selling, general and administrative expense. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold. |
Patents | Patents We have filed a number of patent applications with the United States Patent and Trademark Office and in foreign countries. Certain legal and related costs incurred in connection with pending patent applications have been capitalized. Costs related to successful patent applications are amortized over the lesser of the remaining useful life of the related technology or the remaining patent life, commencing on the date the patent is issued. Capitalized costs related to patent applications are expensed in the period in which a determination is made not to pursue such applications. |
Impairment of Long-Lived Assets | Impairment of Long-Lived Assets In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. There were no patent impairments during the years ended July 31, 2019 or 2018. |
Revenue Recognition | Revenue Recognition Effective August 1, 2018, we adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process: 1. Identify the contract with the customer 2. Identify the performance obligations in the contract 3. Determine the transaction price 4. Allocate the transaction price to the performance obligations in the contract 5. Recognize revenue when (or as) each performance obligation is satisfied Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control® as a direct food contact processing aid. Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price. Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Our direct customer and distributer sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns. Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales. We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. Variable Consideration We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur. Practical Expedient We elected a practical expedient to expense sales commissions when the commissions are incurred because the amortization period would have been one year or less. These costs are recorded as Selling, general and administrative expense on our Consolidated Statements of Operations. |
Shipping and Handling Costs | Shipping and Handling Costs Shipping and handling costs incurred by us for product shipments are included in cost of goods sold and were minimal for the years ended July 31, 2019 and 2018. |
Research and Development Costs | Research and Development Costs Research and development costs are expensed as incurred. |
Share-Based Compensation | Share-Based Compensation We grant equity-based awards under share-based compensation plans. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. |
Comprehensive Loss | Comprehensive Loss Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on marketable securities and foreign currency translation adjustments. For the years ended July 31, 2019 and 2018, our comprehensive loss consisted only of net loss. |
Income Taxes | Income Taxes We recognize deferred tax assets and liabilities for temporary differences between the tax basis of assets and liabilities and the amounts at which they are carried in the financial statements based upon the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established to reduce deferred tax assets to the amount expected to be realized. |
Net Loss Per Share | Net Loss Per Share Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an antidilutive effect. For the years ended July 31, 2019 and 2018, the number of shares issuable upon the exercise of stock options, the vesting of restricted stock units, and the exercise of warrants, none of which are included in the computation of basic net loss per common share, was 9,736,722 and 12,012,189, respectively. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In May 2014, the FASB issued Topic 606, which supersedes most existing revenue recognition guidance in U.S. generally accepted accounting principles (“GAAP”), including most industry-specific guidance. The standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The new standard was originally effective for public companies for annual reporting periods beginning after December 15, 2016, with no early application permitted. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers, which deferred by one year the effective date for all entities, with application permitted as of the original effective date. The standard allows for either a full retrospective or modified retrospective method of adoption. We adopted the new standard for the fiscal year beginning August 1, 2018 using the modified retrospective application method. Under this method, entities recognize the cumulative impact of applying the new standard at the date of adoption without restatement of prior periods presented. The cumulative effect of applying the new standard to contracts that were not completed as of August 1, 2018 did not have a material impact on our consolidated financial position, results of operations, or cash flows. The new standard also requires enhanced disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. Topic 606 supersedes the revenue recognition requirements in ASC Topic 605, Revenue Recognition (“Topic 605”). While results for reporting periods beginning after August 1, 2018 are presented under Topic 606, all prior period amounts are not adjusted and continue to be reported under the accounting standards in effect during these prior periods. The accounting policies for revenue recognition for periods prior to August 1, 2018 are described in “Note 2. Summary of Significant Accounting Policies” of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended July 31, 2018. Adoption of this ASC did not have a material impact on our consolidated financial statements. Refer to the revenue recognition disclosure above. In July 2017, the Financial Accounting Standards Board (“FASB”) issued a two-part Accounting Standards Update (“ASU”) No. 2017-11, I. Accounting for Certain Financial Instruments With Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception (“ASU 2017-11”). ASU 2017-11 amends guidance in FASB ASC 260, Earnings Per Share, FASB ASC 480, Distinguishing Liabilities from Equity, and FASB ASC 815, Derivatives and Hedging. The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 with early adoption permitted. The adoption of this guidance had no impact on our financial statements as all derivative liabilities were all exercised or expired as of July 31, 2018. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The standard clarifies the presentation of restricted cash and cash equivalents and requires companies to include restricted cash and cash equivalents in the beginning and ending balances of cash and cash equivalents on the statement of cash flows. The standard also requires additional disclosures to describe the amount and detail of the restriction by balance sheet line item. The new standard was effective for us on August 1, 2018. We adopted this standard using the retrospective transition method by restating the consolidated statements of cash flows to include restricted cash of $75,000 in the beginning and ending cash, cash equivalents, and restricted cash balance. Net cash flows for the fiscal year ended July 31, 2018, did not change as a result of including restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts presented on the statements of cash flows. In December 2017, the United States (“U.S.”) enacted the Tax Cuts and Jobs Act (the “2017 Act”), which changes existing U.S. tax law and includes various provisions that are expected to affect public companies. The 2017 Act (i) changes U.S. corporate tax rates, (ii) generally reduces a company’s ability to utilize accumulated net operating losses, and (iii) requires the calculation of a one-time transition tax on certain previously unrepatriated foreign earnings and profits (“E&P”). The 2017 Act will also impact estimates of a company’s deferred tax assets and liabilities. On December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed in reasonable detail to complete the accounting for certain income tax effects of the Tax Cuts and Jobs Act (“U.S. Tax Cuts and Jobs Act of 2017”). This new law did not have a significant impact on our consolidated financial statements for the years ended July 31, 2019 and 2018 because we maintain a valuation allowance on the entirety of our deferred tax assets. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, which provides clarity and guidance around which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting. The new standard was effective for annual reporting periods beginning after April 1, 2018, and interim periods within those annual reporting periods. The adoption of this guidance had no impact on our financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting, which aligns the measurement and classification guidance for share-based payment to non-employees with the guidance for share-based payments to employees. Under the new guidance, the measurement period for equity-classified non-employee awards will be fixed at the grant date. This update is effective for annual periods beginning after December 15, 2018, and interim periods within those periods and early adoption is permitted. We elected to early adopt ASU No. 2018-07 during the fiscal year ended July 31, 2019. The adoption of this guidance had no material impact on our financial statements. |
Balance Sheet Details (Tables)
Balance Sheet Details (Tables) | 12 Months Ended |
Jul. 31, 2019 | |
Balance Sheet Related Disclosures [Abstract] | |
Schedule of Inventories | Inventories consist of the following: July 31, 2019 2018 Raw materials $ 30,000 $ 39,000 Finished goods 147,000 158,000 $ 177,000 $ 197,000 |
Schedule of Property Plant and Equipment | Property, plant, and equipment consist of the following: July 31, 2019 2018 Computers and equipment $ 1,001,000 $ 1,064,000 Furniture and fixtures 21,000 21,000 1,022,000 1,085,000 Less accumulated depreciation (660,000 ) (624,000 ) $ 362,000 $ 461,000 |
Schedule of Patents | Patents consist of the following: July 31, 2019 2018 Patents $ 3,504,000 $ 3,500,000 Less accumulated amortization (2,975,000 ) (2,842,000 ) $ 529,000 $ 658,000 |
Schedule of Future Patent Amortization Expense | At July 31, 2019, future patent amortization expense is expected to be as follows: 2020 $ 87,000 2021 76,000 2022 48,000 2023 42,000 2024 42,000 Thereafter 234,000 $ 529,000 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 12 Months Ended |
Jul. 31, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Future Minimum Annual Lease Payments | Future minimum annual lease payments for our primary facility as of July 31, 2019 are as follows: 2019 $ 37,000 2020 $ 14,000 $ 51,000 |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments (Tables) | 12 Months Ended |
Jul. 31, 2019 | |
Fair Value Disclosures [Abstract] | |
Schedule of Derivative Liabilities at Fair Value | The following table provides a reconciliation of the beginning and ending balances of the derivative liabilities for the year ended July 31, 2018: Fair Value of Significant Unobservable Inputs (Level 3) Warrant Liability Balance at July 31, 2017 $ 1,853,000 Issuances — Settlement of warrant liability (1,394,000 ) Adjustments to estimated fair value (459,000 ) Balance at July 31, 2018 $ — |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 12 Months Ended |
Jul. 31, 2019 | |
Stockholders' equity | |
Schedule of Warrant Activity | A summary of our warrant activity and related data is as follows: Shares Outstanding at July 31, 2017 8,303,836 Issued — Exercised (5,329,220 ) Expired/Cancelled (113,520 ) Outstanding at July 31, 2018 2,861,096 Issued — Exercised (2,399,999 ) Expired/Cancelled — Outstanding at July 31, 2019 461,097 |
Schedule of Warrants Outstanding | The following table summarizes information related to warrants outstanding at July 31, 2019: Expiration Exercise Date Price Shares 08/29/19 $ 0.75 133,332 12/01/21 $ 1.25 58,824 12/01/21 $ 1.28 117,647 01/23/22 $ 1.25 117,647 01/23/22 $ 1.28 33,647 461,097 |
Share-Based Compensation (Table
Share-Based Compensation (Tables) | 12 Months Ended |
Jul. 31, 2019 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Restricted Stock Activity | A summary of our restricted stock unit activity and related data is as follows: Shares Outstanding at July 31, 2017 2,035,000 Granted 750,000 Vested (375,000 ) Forfeited (885,000 ) Outstanding at July 31, 2018 1,525,000 Granted 725,000 Vested (206,250 ) Forfeited (131,250 ) Outstanding at July 31, 2019 1,912,500 |
Schedule of Stock Option Activity | A summary of our stock option activity for the fiscal years ended July 31, 2019 and 2018 is as follows: Shares Weighted- Aggregate Outstanding at July 31, 2017 5,759,843 $ 1.25 $ 1,120,000 Granted 2,245,000 $ — Exercised — $ — Cancelled (378,750 ) $ 1.96 Outstanding at July 31, 2018 7,626,093 $ 1.09 $ — Granted 300,000 $ 0.52 Exercised — $ — Cancelled (562,968 ) $ 1.47 Outstanding at July 31, 2019 7,363,125 $ 1.04 $ — |
Schedule of Fair Value Assumptions | The fair value of stock options was estimated at the grant date using the following weighted average assumptions: For the years ended July 31, 2019 2018 Volatility 75.67 % 71.18 % Risk-free interest rate 2.63 % 2.32 % Dividend yield 0.0 % 0.0 % Expected life 4.80 years 3.69 years |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Jul. 31, 2019 | |
Income Tax Disclosure [Abstract] | |
Schedule of Deferred Tax Assets | Significant components of our deferred tax assets are as follows: July 31, 2019 2018 Net operating loss carry-forward $ 26,940,000 $ 26,170,000 Stock options and warrants 2,030,000 2,590,000 Other temporary differences (130,000 ) (130,000 ) Total deferred tax assets 28,840,000 28,630,000 Valuation allowance for deferred tax assets (28,840,000 ) (28,630,000 ) Net deferred tax assets $ — $ — |
Schedule of Reconciliation Effective Tax Rate, Percentage | A reconciliation of income taxes computed using the statutory income tax rate, compared to the effective tax rate, is as follows: 2019 2018 Federal tax benefit at the expected statutory rate 21.0 % 26.4 % State income tax, net of federal tax benefit 0.6 32.5 Expired net operating loss carryforwards — (20.0 ) Other (18.3 ) (2.9 ) Rate change adjustment — (175.4 ) Change in state tax rates — — Permanent items — — Valuation allowance (3.3 ) 139.4 Income tax benefit - effective rate 0.0 % 0.0 % |
Organization and Business (Deta
Organization and Business (Details Narrative) - USD ($) | Oct. 02, 2019 | Aug. 16, 2018 | Jul. 31, 2019 | Jul. 31, 2019 | Jul. 31, 2018 |
Cumulative net loss | $ 123,478,000 | $ 123,478,000 | $ 116,924,000 | ||
Cash and cash equivalents | 398,000 | 398,000 | 851,000 | ||
Current liabilities | 738,000 | 738,000 | 1,281,000 | ||
Accounts payable | $ 553,000 | 553,000 | 608,000 | ||
Net proceeds from issuance common stock | $ 1,710,000 | ||||
Private Placement [Member] | |||||
Number of shares issued | 3,333,964 | 2,468,963 | |||
Purchase price per share | $ 0.45 | $ 0.29 | $ 0.29 | ||
Private Placement [Member] | Dale Okuno [Member] | |||||
Investments amount | $ 250,000 | $ 250,000 | |||
Subsequent Event [Member] | Private Placement [Member] | |||||
Net proceeds from issuance common stock | $ 830,000 | ||||
Number of shares issued | 2,862,068 | ||||
Purchase price per share | $ 0.29 | ||||
Subsequent Event [Member] | Private Placement [Member] | Tom Y. Lee [Member] | |||||
Investments amount | $ 290,000 | ||||
Subsequent Event [Member] | Private Placement [Member] | Dale Okuno [Member] | |||||
Investments amount | $ 250,000 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Details Narrative) - USD ($) | 12 Months Ended | ||
Jul. 31, 2019 | Jul. 31, 2018 | Nov. 30, 2016 | |
Restricted cash | $ 75,000 | $ 75,000 | |
Allowance for doubtful accounts receivable | 0 | 0 | |
Impairment of patents | |||
Computation of basic net loss per share | 9,736,722 | 12,012,189 | |
Minimum [Member] | |||
Estimated useful lives of property, plant and equipment | 3 years | ||
Maximum [Member] | |||
Estimated useful lives of property, plant and equipment | 10 years | ||
Accounting Standards Update 2016-18 [Member] | |||
Restricted cash | $ 75,000 |
Balance Sheet Details (Details
Balance Sheet Details (Details Narrative) - USD ($) | 12 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Inventory written off | $ 58,000 | |
Insurance claim for replacement cost of inventory | 45,000 | |
Gain on inventories | 19,000 | |
Depreciation expense | 106,000 | 106,000 |
Patent amortization expense | $ 135,000 | 179,000 |
Third-Party Warehouse Fire [Member] | ||
Inventory written off | $ 26,000 |
Balance Sheet Details - Schedul
Balance Sheet Details - Schedule of Inventories (Details) - USD ($) | Jul. 31, 2019 | Jul. 31, 2018 |
Balance Sheet Related Disclosures [Abstract] | ||
Raw materials | $ 30,000 | $ 39,000 |
Finished goods | 147,000 | 158,000 |
Inventory, net | $ 177,000 | $ 197,000 |
Balance Sheet Details - Sched_2
Balance Sheet Details - Schedule of Property Plant and Equipment (Details) - USD ($) | Jul. 31, 2019 | Jul. 31, 2018 |
Property, plant, and equipment | $ 1,022,000 | $ 1,085,000 |
Less accumulated depreciation | (660,000) | (624,000) |
Property, plant, and equipment, net | 362,000 | 461,000 |
Computer and Equipment [Member] | ||
Property, plant, and equipment | 1,001,000 | 1,064,000 |
Furniture and Fixtures [Member] | ||
Property, plant, and equipment | $ 21,000 | $ 21,000 |
Balance Sheet Details - Sched_3
Balance Sheet Details - Schedule of Patents (Details) - USD ($) | Jul. 31, 2019 | Jul. 31, 2018 |
Balance Sheet Related Disclosures [Abstract] | ||
Patents | $ 3,504,000 | $ 3,500,000 |
Less accumulated amortization | (2,975,000) | (2,842,000) |
Patents, net | $ 529,000 | $ 658,000 |
Balance Sheet Details - Sched_4
Balance Sheet Details - Schedule of Future Patent Amortization Expense (Details) - USD ($) | Jul. 31, 2019 | Jul. 31, 2018 |
Balance Sheet Related Disclosures [Abstract] | ||
2020 | $ 87,000 | |
2021 | 76,000 | |
2022 | 48,000 | |
2023 | 42,000 | |
2024 | 42,000 | |
Thereafter | 234,000 | |
Patents, net | $ 529,000 | $ 658,000 |
Commitments and Contingencies_2
Commitments and Contingencies (Details Narrative) - USD ($) | Jul. 25, 2019 | Aug. 31, 2016 | Jul. 31, 2019 | Jul. 31, 2018 |
Lease expiration date, description | We amended the lease of our primary facility in El Cajon, California under a noncancelable operating lease that now expires in December 2019. | |||
Rent expense per month | $ 111,000 | $ 121,000 | ||
Sublease Agreement [Member] | SwabPlus L.P. [Member] | ||||
Rent expense per month | $ 2,333 |
Commitments and Contingencies -
Commitments and Contingencies - Schedule of Future Minimum Annual Lease Payments (Details) | Jul. 31, 2019USD ($) |
Commitments and Contingencies Disclosure [Abstract] | |
2019 | $ 37,000 |
2020 | 14,000 |
Total | $ 51,000 |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments - Schedule of Derivative Liabilities at Fair Value (Details) - Fair Value, Inputs, Level 3 [Member] - Warrant Liability [Member] | 12 Months Ended |
Jul. 31, 2018USD ($) | |
Balance at July 31, 2017 | $ 1,853,000 |
Issuances | |
Settlement of warrant liability | (1,394,000) |
Adjustments to estimated fair value | (459,000) |
Balance at July 31, 2018 |
Derivative Liability (Details N
Derivative Liability (Details Narrative) - USD ($) | Sep. 25, 2017 | Jul. 31, 2019 | Jul. 31, 2018 | Oct. 10, 2017 | Nov. 30, 2015 | Oct. 31, 2015 |
Change in fair value of warrant liabilities | $ 459,000 | |||||
2015 Private Placement Financing [Member] | ||||||
Number of warrants issued | 20,376,219 | 20,376,219 | ||||
Number of warrants to purchase common stock | 1,599,135 | 268,909 | ||||
Number of warrants exercised during period | 118,057 | |||||
Issuance of share of common stock | 63,811 |
Promissory Note Payable (Detail
Promissory Note Payable (Details Narrative) - USD ($) | Aug. 16, 2018 | Jun. 28, 2018 | Jul. 31, 2019 | Jul. 31, 2018 |
Proceeds from issuance of promissory note | $ 500,000 | |||
Principal amount | $ 500,000 | |||
Accrued interest | $ 4,000 | |||
Debt conversion converted into stock | 1,120,633 | |||
Promissory Note [Member] | Mr. Tom Y. Lee [Member] | ||||
Proceeds from issuance of promissory note | $ 500,000 | |||
Debt instrument term | 1 year | |||
Debt instrument interest rate | 6.50% | |||
Principal amount | $ 500,000 | |||
Accrued interest | $ 4,000 | |||
Debt conversion converted into stock | 1,120,633 |
Stockholders' Equity (Details N
Stockholders' Equity (Details Narrative) - USD ($) | Feb. 19, 2019 | Aug. 16, 2018 | Sep. 25, 2017 | Apr. 13, 2016 | Jul. 31, 2019 | Oct. 31, 2017 | Apr. 30, 2018 | Jul. 31, 2019 | Jul. 31, 2018 | Jan. 23, 2017 | Nov. 23, 2015 | Aug. 29, 2014 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 | 5,000,000 | |||||||||
Preferred stock, shares par value | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||
Preferred stock, shares issued | ||||||||||||
Preferred stock, shares outstanding | ||||||||||||
Common stock, shares authorized | 100,000,000 | 100,000,000 | 100,000,000 | |||||||||
Common stock, shares par value | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||
Inducement to exercise warrants | $ 876,000 | $ 960,000 | $ 876,000 | |||||||||
Proceeds from issuance of common stock | 1,710,000 | |||||||||||
Proceeds from warrant exercise | 840,000 | 2,632,000 | ||||||||||
Value of shares issued for services | 172,000 | |||||||||||
Two Year Service Agreement [Member] | Business Development Services [Member] | ||||||||||||
Number of common shares issued for services | 50,000 | |||||||||||
Value of shares issued for services | $ 51,000 | $ 25,000 | 21,000 | |||||||||
Two Year Service Agreement [Member] | General Financial Advisory Services [Member] | ||||||||||||
Number of common shares issued for services | 250,000 | |||||||||||
Value of shares issued for services | $ 290,000 | $ 101,000 | ||||||||||
2014 Warrants [Member] | ||||||||||||
Number of common stock shares issued | 1,491,649 | |||||||||||
Warrant exercise price per share | $ 0.75 | $ 0.75 | ||||||||||
Number of warrants to purchase common stock | 2,399,999 | 2,533,331 | 2,533,331 | |||||||||
Aggregate value of exercise price of warrants | $ 840,000 | |||||||||||
Inducement to exercise warrants | $ 960,000 | |||||||||||
2014 Warrants [Member] | Maximum [Member] | ||||||||||||
Warrant exercise price per share | $ 0.75 | |||||||||||
2014 Warrants [Member] | Minimum [Member] | ||||||||||||
Warrant exercise price per share | $ 0.35 | |||||||||||
2015 Warrants [Member] | ||||||||||||
Number of common stock shares issued | 1,599,135 | |||||||||||
2017 Warrants [Member] | ||||||||||||
Number of common stock shares issued | 1,396,470 | |||||||||||
Warrant exercise price per share | $ 1.25 | $ 1.25 | ||||||||||
Number of warrants to purchase common stock | 176,471 | 176,471 | ||||||||||
Proceeds from issuance of common stock | $ 2,720,000 | |||||||||||
Original Warrants [Member] | ||||||||||||
Warrant expiration date | Sep. 25, 2017 | Sep. 25, 2017 | ||||||||||
Number of warrants exercised during period | 198,057 | |||||||||||
2015 Warrants [Member] | ||||||||||||
Number of warrants to purchase common stock | 268,909 | 268,909 | ||||||||||
Proceeds from warrant exercise | $ 107,000 | |||||||||||
2015 Warrants [Member] | Garden State Securities Inc [Member] | ||||||||||||
Number of warrants to purchase common stock | 4,756,163 | 4,756,163 | ||||||||||
Proceeds from warrant exercise | $ 2,632,000 | |||||||||||
Warrant [Member] | ||||||||||||
Number of common stock shares issued | 158,342 | |||||||||||
Number of warrants exercised during period | 573,057 | |||||||||||
Mr. Tom Y. Lee [Member] | ||||||||||||
Investments amount | $ 1,000,000 | |||||||||||
Investment cash | 500,000 | |||||||||||
Conversion of indebtedness amount | 500,000 | |||||||||||
Mr. Tom Y. Lee [Member] | 2014 Warrants [Member] | ||||||||||||
Number of warrants to purchase common stock | 2,133,333 | |||||||||||
Aggregate value of exercise price of warrants | $ 746,666 | |||||||||||
Dale Okuno [Member] | 2014 Warrants [Member] | ||||||||||||
Number of warrants to purchase common stock | 213,333 | |||||||||||
Aggregate value of exercise price of warrants | $ 74,666 | |||||||||||
Investors [Member] | 2014 Warrants [Member] | ||||||||||||
Number of warrants to purchase common stock | 4,104,980 | |||||||||||
Investors [Member] | 2014 Warrants [Member] | Maximum [Member] | ||||||||||||
Price per share | $ 0.75 | |||||||||||
Investors [Member] | 2014 Warrants [Member] | Minimum [Member] | ||||||||||||
Price per share | $ 0.60 | |||||||||||
Investors [Member] | 2015 Warrants [Member] | ||||||||||||
Number of warrants to purchase common stock | 1,986,101 | |||||||||||
Investors [Member] | 2015 Warrants [Member] | Maximum [Member] | ||||||||||||
Price per share | $ 0.45 | |||||||||||
Investors [Member] | 2015 Warrants [Member] | Minimum [Member] | ||||||||||||
Price per share | $ 0.40 | |||||||||||
Investors [Member] | 2017 Warrants [Member] | ||||||||||||
Number of warrants to purchase common stock | 1,572,941 | |||||||||||
Investors [Member] | 2017 Warrants [Member] | Maximum [Member] | ||||||||||||
Price per share | $ 1.25 | |||||||||||
Investors [Member] | 2017 Warrants [Member] | Minimum [Member] | ||||||||||||
Price per share | $ 0.85 | |||||||||||
Private Placement [Member] | ||||||||||||
Closing value of common stock shares | $ 1,500,000 | |||||||||||
Number of common stock shares issued | 3,333,964 | 2,468,963 | ||||||||||
Price per share | $ 0.45 | $ 0.29 | $ 0.29 | |||||||||
Conversion amount | $ 500,000 | |||||||||||
Net proceeds from private placement financing | $ 1,500,000 | $ 716,000 | ||||||||||
Private Placement [Member] | Dale Okuno [Member] | ||||||||||||
Investments amount | 250,000 | $ 250,000 | ||||||||||
Private Placement [Member] | Ivan Chen [Member] | ||||||||||||
Investments amount | $ 35,000 | $ 35,000 |
Stockholders' Equity - Schedule
Stockholders' Equity - Schedule of Warrant Activity (Details) - shares | 12 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Stockholders' equity | ||
Warrants Outstanding, Beginning balance | 2,861,096 | 8,303,836 |
Warrants Issued | ||
Warrants Exercised | (2,399,999) | (5,329,220) |
Warrants Expired/Cancelled | (113,520) | |
Warrants Outstanding, Ending balance | 461,097 | 2,861,096 |
Stockholders' Equity - Schedu_2
Stockholders' Equity - Schedule of Warrants Outstanding (Details) - $ / shares | Jul. 31, 2019 | Jul. 31, 2018 | Jul. 31, 2017 |
Shares, Warrants | 461,097 | 2,861,096 | 8,303,836 |
08/29/19 [Member] | |||
Expiration Date, Warrants | Aug. 29, 2019 | ||
Exercise Price, Warrants | $ 0.75 | ||
Shares, Warrants | 133,332 | ||
Warrant 2 [Member] | |||
Expiration Date, Warrants | Dec. 1, 2021 | ||
Exercise Price, Warrants | $ 1.25 | ||
Shares, Warrants | 58,824 | ||
Warrant 3 [Member] | |||
Expiration Date, Warrants | Dec. 1, 2021 | ||
Exercise Price, Warrants | $ 1.28 | ||
Shares, Warrants | 117,647 | ||
Warrant 4 [Member] | |||
Expiration Date, Warrants | Jan. 23, 2022 | ||
Exercise Price, Warrants | $ 1.25 | ||
Shares, Warrants | 117,647 | ||
Warrant 5 [Member] | |||
Expiration Date, Warrants | Jan. 23, 2022 | ||
Exercise Price, Warrants | $ 1.28 | ||
Shares, Warrants | 33,647 |
Share-Based Compensation (Detai
Share-Based Compensation (Details Narrative) - USD ($) | Oct. 04, 2018 | Feb. 29, 2016 | Jul. 31, 2019 | Jul. 31, 2018 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Restricted stock units outstanding | 76,732,334 | 68,248,158 | ||
Share-based compensation | $ 1,387,000 | $ 1,525,000 | ||
Options issued to purchase common stock | 6,354,792 | |||
Options expirations term | 4 years 7 months 6 days | |||
Weighted average exercise price | $ 1.04 | |||
Weighted average contractual term | 4 years 3 months 26 days | |||
Weighted average grant date fair value for options granted | $ 0.52 | $ 0.44 | ||
Unrecognized compensation cost of unvested stock option grants | $ 312,000 | |||
Weighted-average contractual term of expected to vest | 1 year 10 months 17 days | |||
Board of Directors [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Options issued to purchase common stock | 200,000 | |||
Option vested description | The options vest over a two year period and carry a ten year term | |||
Board of Directors [Member] | Business Development Activities [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Options issued to purchase common stock | 100,000 | |||
Option vested description | The options vest monthly over a two year period and carry a five year term. | |||
Employees, Directors and Consultants [Member] | Stock Option [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based compensation | $ 203,000 | |||
Options issued to purchase common stock | 2,245,000 | |||
Option vested description | The options vest between one and two years and carry a term between five and ten years. | |||
Number of share options expiration terms extended | 740,000 | |||
Options expirations term | 3 years | |||
2007 Equity Incentive Plan [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Common stock shares increase under the plan | 4,000,000 | |||
Share-based compensation, expiration date | Feb. 4, 2026 | |||
Contractual life vesting periods | 10 years | |||
Number of shares available for issuance under the plan | 1,153,000 | |||
2017 Equity Incentive Plan [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Contractual life vesting periods | 10 years | |||
Number of shares available for issuance under the plan | 2,071,000 | |||
Common stock, shares reserved | 5,000,000 | |||
Restricted Stock Units RSU [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of shares not expected to vest | 300,000 | |||
Unvested restricted stock units outstanding | 1,912,500 | |||
Shares expected to vest | 456,250 | |||
Unrecognized non-cash compensation costs | $ 207,000 | |||
Unrecognized non-cash compensation costs, weighted average period | 1 year 9 months 18 days | |||
Restricted stock units outstanding | 1,912,500 | |||
RSUs vested and non-delivered underlying common stock | 1,456,250 | |||
Share-based compensation | $ 1,062,000 | $ 834,000 | ||
Restricted Stock Units RSU [Member] | Board of Directors [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock issued during period, shares, share-based compensation | 725,000 | 450,000 | ||
Share-based compensation, vesting period | 2 years | |||
Share-based payment award, expiration period | 10 years | |||
Restricted stock units vested percentage | 50.00% | |||
Restricted Stock Units RSU [Member] | Tom Myers [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock issued during period, shares, share-based compensation | 500,000 | |||
Share-based compensation, vesting period | 3 years | |||
Restricted Stock Units RSU [Member] | Third-Party Consultants [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock issued during period, shares, share-based compensation | 300,000 | |||
Share-based compensation description | We issued 300,000 performance based RSUs to third-party consultants. We currently do not expect the 300,000 RSUs to vest. | |||
Restricted Stock Units RSU [Member] | Mr. Pfanzelter [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Restricted shares units vested amount | $ 489,000 |
Share-Based Compensation - Sche
Share-Based Compensation - Schedule of Restricted Stock Activity (Details) - shares | 12 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Share-based Payment Arrangement [Abstract] | ||
Outstanding, Beginning balance | 1,525,000 | 2,035,000 |
Granted | 725,000 | 750,000 |
Vested | (206,250) | (375,000) |
Forfeited | (131,250) | (885,000) |
Outstanding, Ending balance | 1,912,500 | 1,525,000 |
Share-Based Compensation - Sc_2
Share-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($) | 12 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Share-based Payment Arrangement [Abstract] | ||
Options Outstanding Shares, Beginning Balance | 7,626,093 | 5,759,843 |
Options Granted, Shares | 300,000 | 2,245,000 |
Options Exercised, Shares | ||
Options Cancelled, Shares | (562,968) | (378,750) |
Options Outstanding Shares, Ending Balance | 7,363,125 | 7,626,093 |
Weighted Average Exercise Price Outstanding, Beginning Balance | $ 1.09 | $ 1.25 |
Weighted Average Exercise Price Granted | 0.52 | |
Weighted Average Exercise Price Exercised | ||
Weighted Average Exercise Price Cancelled | 1.47 | 1.96 |
Weighted Average Exercise Price Outstanding, Ending Balance | $ 1.04 | $ 1.09 |
Aggregate Intrinsic Value Outstanding, Beginning Balance | $ 1,120,000 | |
Aggregate Intrinsic Value Outstanding, Ending Balance |
Share-Based Compensation - Sc_3
Share-Based Compensation - Schedule of Fair Value Assumptions (Details) | 12 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Share-based Payment Arrangement [Abstract] | ||
Volatility | 75.67% | 71.80% |
Risk-free interest rate | 2.63% | 2.32% |
Dividend yield | 0.00% | 0.00% |
Expected life | 4 years 9 months 18 days | 3 years 8 months 9 days |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | Jun. 09, 2019 | Aug. 16, 2018 | Jun. 28, 2018 | Jul. 31, 2019 | Jul. 31, 2018 |
Proceeds from issuance of promissory note | $ 500,000 | ||||
Principal amount | $ 500,000 | ||||
Accrued interest | $ 4,000 | ||||
Debt conversion converted into stock | 1,120,633 | ||||
Net product sales | 1,909,000 | 1,774,000 | |||
Payments to acquire products | 6,000 | 15,000 | |||
SwabPlus Inc [Member] | |||||
Rent Payable | 2,333 | ||||
Intercon Chemical Company [Member] | |||||
Net product sales | 5,000 | 8,000 | |||
Payments to acquire products | 540,000 | 575,000 | |||
Payable to related parties | 65,000 | 85,000 | |||
Accounts receivable | |||||
Intercon Chemical Company [Member] | Manufacturing Supply Agreement [Member] | |||||
Related party description | We entered into a five-year manufacturing supply agreement with Intercon Chemical Company (ICC) with a three-year renewal term option (the "Manufacturing Supply Agreement"). The agreement consists of manufacturing, packaging, and distribution of PURE's SDC-based products. | ||||
Tom Y. Lee [Member] | |||||
Proceeds from issuance of promissory note | $ 500,000 | ||||
Debt instrument term | 1 year | ||||
Debt instrument interest rate | 6.50% |
Sales Concentration (Details Na
Sales Concentration (Details Narrative) - USD ($) | 12 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Net product sales | $ 1,909,000 | $ 1,774,000 |
Sales Revenue [Member] | One Individual Customer [Member] | ||
Concentration risk percentage | 15.00% | 20.00% |
Sales Revenue [Member] | Two Individual Customers [Member] | ||
Concentration risk percentage | 11.00% | 16.00% |
Sales Revenue [Member] | No Other Individual Customer [Member] | ||
Concentration risk percentage | 10.00% | 10.00% |
Sales Revenue [Member] | Customer Three [Member] | ||
Concentration risk percentage | 11.00% |
Income Taxes (Details Narrative
Income Taxes (Details Narrative) - USD ($) | 12 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Provision for income tax | $ 1,650 | $ 1,650 |
Federal operating loss carry forwards | 108,300,000 | 105,200,000 |
State operating loss carry forward | $ 62,100,000 | 60,500,000 |
Ownership change percentage | 50.00% | |
Accrued interest or penalties | ||
Unrecognized tax benefits | ||
Federal [Member] | ||
Operating loss carryforwards, expiration date | Jul. 31, 2038 | |
Federal [Member] | Carried Forward Indefinitely [Member] | ||
Federal operating loss carry forwards | $ 3,100,000 | |
State [Member] | ||
Operating loss carryforwards, expiration date | Jul. 31, 2039 |
Income Taxes - Schedule of Defe
Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($) | Jul. 31, 2019 | Jul. 31, 2018 |
Income Tax Disclosure [Abstract] | ||
Net operating loss carry-forward | $ 26,940,000 | $ 26,170,000 |
Stock options and warrants | 2,030,000 | 2,590,000 |
Other temporary differences | (130,000) | (130,000) |
Total deferred tax assets | 28,840,000 | 28,630,000 |
Valuation allowance for deferred tax assets | (28,840,000) | (28,630,000) |
Net deferred tax assets |
Income Taxes - Schedule of Reco
Income Taxes - Schedule of Reconciliation Effective Tax Rate, Percentage (Details) | 12 Months Ended | |
Jul. 31, 2019 | Jul. 31, 2018 | |
Income Tax Disclosure [Abstract] | ||
Federal tax benefit at the expected statutory rate | 21.00% | 26.40% |
State income tax, net of federal tax benefit | 0.46% | 32.50% |
Expired net operating loss carryforwards | (20.00%) | |
Other | (18.30%) | (2.90%) |
Rate change adjustment | 175.40% | |
Change in state tax rates | ||
Permanent items | ||
Valuation allowance | 3.30% | 139.40% |
Income tax benefit - effective rate | 0.00% | 0.00% |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - USD ($) | Oct. 02, 2019 | Aug. 16, 2018 | Jul. 31, 2019 | Jul. 31, 2019 | Jul. 31, 2018 |
Proceeds from issuance of common stock | $ 1,710,000 | ||||
Private Placement [Member] | |||||
Number of shares issued | 3,333,964 | 2,468,963 | |||
Purchase price per share | $ 0.45 | $ 0.29 | $ 0.29 | ||
Private Placement [Member] | Dale Okuno [Member] | |||||
Investments amount | $ 250,000 | $ 250,000 | |||
Subsequent Event [Member] | Private Placement [Member] | |||||
Proceeds from issuance of common stock | $ 830,000 | ||||
Number of shares issued | 2,862,068 | ||||
Purchase price per share | $ 0.29 | ||||
Proceeds from private placement after deducting forgoing fees and other offering expenses | $ 829,000 | ||||
Subsequent Event [Member] | Private Placement [Member] | Tom Y. Lee [Member] | |||||
Investments amount | 290,000 | ||||
Subsequent Event [Member] | Private Placement [Member] | Dale Okuno [Member] | |||||
Investments amount | $ 250,000 |